Last reviewed · How we verify
Microscopic polyarteritis nodosa
Approved treatments
- Mabthera · Roche
- Mabthera · Roche
Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC. - Mabthera · Roche
Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Microscopic polyarteritis nodosa patent landscape — cliff calendar, originator estates, attackable patents
- Microscopic polyarteritis nodosa treatment landscape brief
- Microscopic polyarteritis nodosa treatment updates RSS
Frequently asked questions about Microscopic polyarteritis nodosa
What drugs treat Microscopic polyarteritis nodosa?
Tracked treatments include Mabthera.
What is the treatment for Microscopic polyarteritis nodosa?
Standard treatment for Microscopic polyarteritis nodosa includes Mabthera. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Microscopic polyarteritis nodosa patent cliff · Microscopic polyarteritis nodosa CI report
- Treatment: Mabthera · Roche
- Treatment: Mabthera · Roche
- Treatment: Mabthera · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing